Incidence and Determinants of Tuberculosis among Adults Initiating Antiretroviral Therapy - Mozambique, 2004-2008

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Auld, Andrew F ^a   Mbofana, Francisco ^b   Shiraishi, Ray W ^a   Alfredo, Charity ^c   Sanchez, Mauro ^d   Ellerbrock, Tedd V ^a   Nelson, Lisa J ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MINISTRY OF HEALTH   (Mozambique)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ISONIAZID; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PROGNOSIS; RETROSPECTIVE STUDY; SCREENING TEST; SEX DIFFERENCE; TUBERCULOSIS;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MOZAMBIQUE; RETROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 84872773050     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054665     Document Type: Article

References (42)

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic. Available: http://www.unaids.org/globalreport/global_report.htm. Accessed 29 Feb 2012.
2. WHO (2011) Global tuberculosis control 2011. Available: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf. Accessed 18 February 2012.
3. Lawn SD, Kranzer K, Wood R (2009) Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 30: 685-699, viii.
4. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, et al. (2010) Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 10: 489-498.
5. Dembele M, Saleri N, Carvalho AC, Saouadogo T, Hien AD, et al. (2010) Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. Int J Tuberc Lung Dis 14: 318-323.
6. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R, (2009) Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23: 1717-1725.
7. Van Rie A, Westreich D, Sanne I, (2011) Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 56: 349-355.
8. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, et al. (2002) Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 6: 55-63.
9. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, et al. (1993) The mortality and pathology of HIV infection in a west African city. AIDS 7: 1569-1579.
10. Rana F, Hawken MP, Meme HK, Chakaya JM, Githui WA, et al. (1997) Autopsy findings in HIV-1-infected adults in Kenya. J Acquir Immune Defic Syndr Hum Retrovirol 14: 83-85.
11. Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, et al. (2010) The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 7: e1000296.
12. World Health Organization (2006) Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach 2006 revision. Available: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed 29 January 2012.
13. Prasso JE, Scardigli A, El-Sadr W, De Lima J, Justman JE, et al. (2010) Intensified Case Finding for Active Tuberculosis among Adults Enrolled in HIV Care and Treatment at an Urban Hospital in Mozambique. XVIII International AIDS Conference. 18-23 July, Vienna, Austria. Available: http://retroconference.org/2010/PDFs/773.pdf. Accessed 29 February 2012.
14. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, et al. (2011) Four-Year Treatment Outcomes of Adult Patients Enrolled in Mozambique's Rapidly Expanding Antiretroviral Therapy Program. PLoS One 6: e18453.
15. Stringer J, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793.
16. Fairley CK, Permana A, Read TR, (2005) Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med 6: 366-369.
17. Lucas GM, Chaisson RE, Moore RD, (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131: 81-87.
18. Grossberg R, Zhang Y, Gross R, (2004) A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 57: 1107-1110.
19. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
20. Rubin DB (1987) Multiple Imputation for Nonresponse in Surveys. New York: J. Wiley & Sons; 231 p.
21. Royston P, (2004) Multiple imputation of missing values. The Stata Journal 4(3): 227-241.
22. Royston P, (2005) Multiple imputation of missing values: update. The Stata Journal 5(2): 188-201.
23. Royston P, (2005) Multiple imputation of missing values: update of ice. The Stata Journal 5(4): 527-536.
24. White IR, Royston P, (2009) Imputing missing covariate values for the Cox model. Stat Med 28: 1982-1998.
25. Royston P, Carlin JB, White IR, (2009) Multiple imputation of missing values: new features for mim. The Stata Journal 9(2): 252-264.
26. Grambsch PM, Therneau TM, (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526.
27. Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, et al. (2011) Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 15: 571-581.
28. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, et al. (2010) Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 51: 823-829.
29. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, et al. (2011) Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study. PLoS Med 8: e1001067.
30. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, et al. (2009) Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 23: 1875-1880.
31. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, et al. (2010) Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 24: 1323-1328.
32. Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, et al. (2010) Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One 5: e10527.
33. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, et al. (2005) Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 172: 123-127.
34. Lawn SD, Wood R, (2011) Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 204Suppl 4: S1159-1167.
35. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD, (2006) Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 12: 744-751.
36. Namuwenge PM, Mukonzo JK, Kiwanuka N, Wanyenze R, Byaruhanga R, et al. (2012) Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda. Trans R Soc Trop Med Hyg 106: 84-89.
37. World Health Organization (2010) Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Available: http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf. Accessed 29 February 2012.
38. Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, et al. (2005) Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 41: 1772-1782.
39. Lawn SD, Badri M, Wood R, (2005) Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 19: 2109-2116.
40. Gutierrez F, Padilla S, Masia M, Iribarren JA, Moreno S, et al. (2008) Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res 6: 100-107.
41. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, et al. (2006) Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 42: 426-434.
42. Nachega J, Morroni C, Ram D, Efron A, Chaisson RE, et al. (2011) Impact of Concurrent TB Treatment on ART Adherence and Liver Toxicity in HIV-Infected Adults [P-177]. 6th International AIDS Society Conference: Rome, Italy. Available: http://retroconference.org/2011/PDFs/883.pdf. Accessed 29 February 2012.